{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T12:14:55Z","timestamp":1792844095749,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":2149,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Intensive Care"],"published-print":{"date-parts":[[2020]]},"DOI":"10.1186\/s13613-020-00761-w","type":"journal-article","created":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T05:02:48Z","timestamp":1602824568000},"page":"143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Immune-related adverse events: a retrospective look into the future of oncology in the intensive care unit"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5278-8966","authenticated-orcid":false,"given":"Adrien","family":"Joseph","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Simonaggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabelle","family":"Stoclin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Vieillard-Baron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Geri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Oudard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marie","family":"Michot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Lambotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elie","family":"Azoulay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Lemiale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1186\/s13613-020-00761-w_bb0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41416-018-0294-4","article-title":"PD-Loma: a cancer entity with a shared sensitivity to the PD-1\/PD-L1 pathway blockade","volume":"120","author":"Hirsch","year":"2019","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1186\/s13613-020-00761-w_bb0015","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1186\/s13613-020-00761-w_bb0020","doi-asserted-by":"crossref","unstructured":"Geraud A, Gougis P, Vozy A, Anquetil C, Allenbach Y, Romano E, et al. Clinical pharmacology and interplay of immune checkpoint agents: a Yin-Yang balance. Annu Rev Pharmacol Toxicol. 2020.","DOI":"10.1146\/annurev-pharmtox-022820-093805"},{"issue":"2","key":"10.1186\/s13613-020-00761-w_bb0025","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.chest.2017.04.177","article-title":"Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer","volume":"152","author":"Khunger","year":"2017","journal-title":"Chest"},{"issue":"7","key":"10.1186\/s13613-020-00761-w_bb0030","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1186\/s13613-020-00761-w_bb0035","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1164\/rccm.201906-1202ST","article-title":"Knowledge gaps and research priorities in immune checkpoint inhibitor-related pneumonitis. An Official American Thoracic Society Research Statement","volume":"200","author":"Sears","year":"2019","journal-title":"Am J Respir Crit Care Med."},{"issue":"10","key":"10.1186\/s13613-020-00761-w_bb0040","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1001\/jamaneurol.2017.1912","article-title":"neurological complications associated with anti-programmed death 1 (PD-1) antibodies","volume":"74","author":"Kao","year":"2017","journal-title":"JAMA Neurol"},{"issue":"9","key":"10.1186\/s13613-020-00761-w_bb0045","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/s41571-019-0194-4","article-title":"Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors","volume":"16","author":"Graus","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"106","key":"10.1186\/s13613-020-00761-w_bb0050","first-page":"12","article-title":"Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors","volume":"2019","author":"Moreira","year":"1990","journal-title":"Eur J Cancer Oxf Engl (1990)"},{"issue":"8","key":"10.1186\/s13613-020-00761-w_bb0055","doi-asserted-by":"crossref","first-page":"102586","DOI":"10.1016\/j.autrev.2020.102586","article-title":"Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities","volume":"19","author":"Allenbach","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"6","key":"10.1186\/s13613-020-00761-w_bb0060","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/liv.13746","article-title":"Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents","volume":"38","author":"Suzman","year":"2018","journal-title":"Liver Int"},{"issue":"8","key":"10.1186\/s13613-020-00761-w_bb0065","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1111\/liv.14489","article-title":"Immune-related hepatitis related to checkpoint inhibitors: clinical and prognostic factors","volume":"40","author":"Riveiro-Barciela","year":"2020","journal-title":"Liver Int"},{"issue":"1","key":"10.1186\/s13613-020-00761-w_bb0070","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/hep.31227","article-title":"Hepatotoxicity from immune checkpoint inhibitors: a systematic review and management recommendation","volume":"72","author":"Peeraphatdit (Bee)","year":"2020","journal-title":"Hepatology"},{"issue":"21","key":"10.1186\/s13613-020-00761-w_bb0075","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1161\/CIRCULATIONAHA.117.029626","article-title":"Cardiac toxicity of immune checkpoint inhibitors: cardio-oncology meets immunology","volume":"136","author":"Varricchi","year":"2017","journal-title":"Circulation"},{"issue":"13","key":"10.1186\/s13613-020-00761-w_bb0080","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/j.jacc.2019.07.079","article-title":"Cardiovascular toxicities of immune checkpoint inhibitors","volume":"74","author":"Ball","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1186\/s13613-020-00761-w_bb0085","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.034497","article-title":"Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology","volume":"140","author":"Bonaca","year":"2019","journal-title":"Circulation"},{"issue":"10124","key":"10.1186\/s13613-020-00761-w_bb0090","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet Lond Engl"},{"issue":"16","key":"10.1186\/s13613-020-00761-w_bb0095","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"10.1186\/s13613-020-00761-w_bb0100","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1186\/s13613-020-00761-w_bb0105","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1186\/s13613-020-00761-w_bb0110","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"on behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group","year":"2017","journal-title":"J Immunother Cancer."},{"issue":"1","key":"10.1186\/s13613-020-00761-w_bb0115","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1016\/S1470-2045(18)30828-3","article-title":"New therapeutic perspectives to manage refractory immune checkpoint-related toxicities","volume":"20","author":"Martins","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1186\/s13613-020-00761-w_bb0120","doi-asserted-by":"crossref","unstructured":"Esfahani K, Elkrief A, Calabrese C, Lapointe R, Hudson M, Routy B, et al. Moving towards personalized treatments of immune-related adverse events. Nat Rev Clin Oncol. 2020;1\u201312.","DOI":"10.1038\/s41571-020-0352-8"},{"issue":"1","key":"10.1186\/s13613-020-00761-w_bb0125","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s40425-018-0412-0","article-title":"Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis","volume":"6","author":"Johnson","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1186\/s13613-020-00761-w_bb0130","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Safa","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1186\/s13613-020-00761-w_bb0135","doi-asserted-by":"crossref","first-page":"R15","DOI":"10.1186\/cc7713","article-title":"Characteristics and outcomes of cancer patients in European ICUs","volume":"13","author":"Taccone","year":"2009","journal-title":"Crit Care Lond Engl"},{"issue":"130","key":"10.1186\/s13613-020-00761-w_bb0140","first-page":"39","article-title":"The 2016\u20132019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study","volume":"2020","author":"Michot","year":"1990","journal-title":"Eur J Cancer Oxf Engl"},{"issue":"3","key":"10.1186\/s13613-020-00761-w_bb0145","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1186\/s13613-020-00761-w_bb0150","doi-asserted-by":"crossref","first-page":"k4226","DOI":"10.1136\/bmj.k4226","article-title":"Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis","volume":"363","author":"Xu","year":"2018","journal-title":"BMJ"},{"issue":"12","key":"10.1186\/s13613-020-00761-w_bb0155","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1186\/s13613-020-00761-w_bb0160","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13613-019-0487-x","article-title":"Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know?","volume":"9","author":"Groupe de Recherche en Reanimation Respiratoire du patient d\u2019Onco-H\u00e9matologie (Grrr-OH)","year":"2019","journal-title":"Ann Intensive Care."},{"issue":"3","key":"10.1186\/s13613-020-00761-w_bb0165","doi-asserted-by":"crossref","first-page":"255","DOI":"10.6004\/jnccn.2019.0013","article-title":"Management of immunotherapy-related toxicities, version 1.2019","volume":"17","author":"Thompson","year":"2019","journal-title":"J Natl Compr Cancer Netw JNCCN."},{"issue":"4","key":"10.1186\/s13613-020-00761-w_bb0170","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper","volume":"27","author":"Champiat","year":"2016","journal-title":"Ann Oncol"},{"issue":"7756","key":"10.1186\/s13613-020-00761-w_bb0175","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/s41586-019-1162-y","article-title":"Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy","volume":"569","author":"Perez-Ruiz","year":"2019","journal-title":"Nature"},{"issue":"9","key":"10.1186\/s13613-020-00761-w_bb0180","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1001\/jamaoncol.2019.1022","article-title":"Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer","volume":"5","author":"Simonaggio","year":"2019","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1186\/s13613-020-00761-w_bb0185","doi-asserted-by":"crossref","first-page":"e001034","DOI":"10.1136\/jitc-2020-001034","article-title":"Reintroduction of immune-checkpoint inhibitors after immune-related meningitis: a case series of melanoma patients","volume":"8","author":"Cuzzubbo","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"7","key":"10.1186\/s13613-020-00761-w_bb0190","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"3","key":"10.1186\/s13613-020-00761-w_bb0195","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of immune-related adverse events with nivolumab efficacy in non\u2013small-cell lung cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1186\/s13613-020-00761-w_bb0200","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1186\/s13613-020-00761-w_bb0205","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1378\/chest.13-1870","article-title":"Outcomes for patients with cancer admitted to the ICU requiring ventilatory support: results from a prospective multicenter study","volume":"146","author":"Azevedo","year":"2014","journal-title":"Chest"},{"issue":"10","key":"10.1186\/s13613-020-00761-w_bb0210","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review","volume":"28","author":"Khoja","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1186\/s13613-020-00761-w_bb0215","doi-asserted-by":"crossref","unstructured":"Chan KK, Bass AR. Autoimmune complications of immunotherapy: pathophysiology and management. BMJ. 2020. 369. https:\/\/www.bmj.com\/content\/369\/bmj.m736. Accessed 23 July 2020.","DOI":"10.1136\/bmj.m736"},{"issue":"1","key":"10.1186\/s13613-020-00761-w_bb0220","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s40425-019-0645-6","article-title":"Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance","volume":"7","author":"Couey","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"11","key":"10.1186\/s13613-020-00761-w_bb0225","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1136\/gutjnl-2018-316948","article-title":"Enterocolitis due to immune checkpoint inhibitors: a systematic review","volume":"67","author":"Soularue","year":"2018","journal-title":"Gut"},{"issue":"2","key":"10.1186\/s13613-020-00761-w_bb0230","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1681\/ASN.2019070676","article-title":"Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study","volume":"31","author":"Cortazar","year":"2020","journal-title":"J Am Soc Nephrol JASN"},{"issue":"12","key":"10.1186\/s13613-020-00761-w_bb0235","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/nrd.2018.210","article-title":"The clinical trial landscape for PD1\/PDL1 immune checkpoint inhibitors","volume":"17","author":"Tang","year":"2018","journal-title":"Nat Rev Drug Discov"}],"container-title":["Annals of Intensive Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13613-020-00761-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13613-020-00761-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2110582025011823?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2110582025011823?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13613-020-00761-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T07:33:45Z","timestamp":1776670425000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2110582025011823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020]]}},"alternative-id":["S2110582025011823"],"URL":"https:\/\/doi.org\/10.1186\/s13613-020-00761-w","relation":{},"ISSN":["2110-5820"],"issn-type":[{"value":"2110-5820","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune-related adverse events: a retrospective look into the future of oncology in the intensive care unit","name":"articletitle","label":"Article Title"},{"value":"Annals of Intensive Care","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1186\/s13613-020-00761-w","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 The Author(s) 2020. Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}],"article-number":"143"}}